Convergent Therapeutics, Inc.
Barbara Duncan serves as a Board Member at several organizations, including Convergent Therapeutics, Inc., Halozyme, Inc., and Atea Pharmaceuticals, Inc. Additionally, Barbara held the position of Chairperson at Fusion Pharmaceuticals until June 2024 and was a Board Member at Versanis Bio, Adaptimmune, Jounce Therapeutics, Inc., ObsEva SA, Aevi Genomics Medicine, and Innoviva, Inc. Academic qualifications include an MBA from The Wharton School and a BS in Accounting from Louisiana State University.
This person is not in the org chart
This person is not in any teams
Convergent Therapeutics, Inc.
Convergent Therapeutics is a clinical-stage biotechnology company exploring the full potential of dual-targeted combination strategies to treat cancer. Convergent has developed a therapeutic platform that is capable of targeting validated and novel cancer antigens. Building on breakthrough research developed by Dr. Neil Bander at Weill Cornell Medicine, Convergent has demonstrated that dual targeting of surface cancer molecules like Prostate-Specific Membrane Antigen (PSMA) improves antitumor efficacy. By leveraging targeting agents with different bio-distributions, such as monoclonal antibodies and ligands, supra-additive therapeutic doses are delivered to tumor cells without additive toxicity to the patient.